Venetoclax Uses

VENCLEXTA is a BCL-2 inhibitor used:
to treat adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL).
In combination with azacitidine or decitabine or low-dose cytarabine to treat newly-diagnosed acute myeloid leukemia (AML) in adult patient aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Dosage: The recommended dose of venetoclax tablets should be taken with a meal and water at approximately the same time each day. The tablets of venetoclax should be swallowed whole and not chewed, crushed, or broken before swallowing.

Side Effects: The most commonly reported venetoclax vedotin side effects include:

  • Low levels of neutrophils
  • Diarrhea
  • Nausea
  • Nose/Throat infection
  • Tiredness
  • Anemia (low red blood cell counts)

Warnings and Precautions:

  • Monitor patients with venetoclax 100 mg for the complete blood counts throughout the treatment period.
  • Monitor patients with venetoclax closely for signs and symptoms of infection and treat promptly.
  • Avoid administering live attenuated vaccines before, during, or following treatment with venetoclax 50 mg until B-cell recovery occurs.
  • Females of the potential age should avoid pregnancy while on treatment with venetoclax.
  • Nursing mothers with venetoclax 10 mg are advised to not breastfeed their child during therapy.